Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

February 7, 2020 updated by: Therapeutic Advances in Childhood Leukemia Consortium

A Study of Bortezomib With Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia

This is a Phase I/II study of a drug called bortezomib given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). Bortezomib is a drug that has been approved by the Food and Drug Administration (FDA) for treating adults with multiple myeloma which is a type of blood cancer. Bortezomib has been shown to cause cancer cells to die in studies done on animals (mice). Studies have been done that have shown that some adults and children with cancer have shown a response to bortezomib when it is used alone. Studies have also been done in adults to evaluate the dose of bortezomib that can be safely given in combination with other chemotherapy drugs.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

All patients will receive 1 course of chemotherapy unless medical complications prevent the administration of some of the drugs. Treatment will last about 1 month.

Treatment on this study will consist of a combination of 7 anti-cancer medications. The 7 anti-cancer medicines are bortezomib, vincristine, dexamethasone, PEG-asparaginase, doxorubicin, cytarabine (Ara-C), and methotrexate (MTX).

If you are in the Phase I portion of this study, you will be given an assigned dose of bortezomib. The dose of bortezomib will be based on doses given in previous studies done with adults and children. At each dose level of bortezomib, between 3 and 6 children will receive bortezomib in combination with chemotherapy. If the side effects are not too severe, the next group of children will receive a higher dose. The dose will continue to be increased until we find the dose that causes serious side effects. Your dose of bortezomib will not be increased. If you have bad side effects, your dose may be decreased.

The dose used during the Phase 2 part of this study will be determined by the outcome of the Phase I study. The highest dose used in Phase I that was tolerated without serious side effects will be the one used in Phase 2.

Study Type

Interventional

Enrollment (Actual)

31

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
    • New South Wales
      • Randwick, New South Wales, Australia, 2031
        • Sydney Children's Hospital
      • Westmead, New South Wales, Australia, 2145
        • The Children's Hospital at Westmead
  • Brazil
      • São Paulo, Brazil, 04023-062
        • Universidade Federale de Sao Paulo/Hospital Sao Paulo
  • Canada
    • Ontario
      • Toronto, Ontario, Canada, M5G1X8
        • Sick Kids
  • United States
    • California
      • Duarte, California, United States, 91010
        • City of Hope
      • Long Beach, California, United States, 90806
        • Miller Children's Hospital
      • Los Angeles, California, United States, 90027
        • Childrens Hospital Los Angeles
      • Oakland, California, United States, 94618
        • Children's Hospital & Research Center Oakland
      • Palo Alto, California, United States, 94304-1812
        • Stanford University Medical Center
      • San Francisco, California, United States, 94143-0106
        • UCSF School of Medicine
    • District of Columbia
      • Washington, District of Columbia, United States, 20010
        • Children's National Medical Center
    • Florida
      • Miami, Florida, United States, 33136
        • University of Miami Cancer Center
    • Georgia
      • Atlanta, Georgia, United States, 30322
        • Children's Healthcare of Atlanta
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Ann & Robert H. Lurie Children's Hospital of Chicago
    • Maryland
      • Baltimore, Maryland, United States, 21231
        • Johns Hopkins / Sydney Kimmel Cancer Center
    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Dana Farber Cancer Center
    • Michigan
      • Ann Arbor, Michigan, United States, 48109-0914
        • C.S. Mott Children's Hospital
    • Minnesota
      • Minneapolis, Minnesota, United States, 55404-4597
        • Childrens Hospital & Clinics of Minnesota
    • New York
      • New York, New York, United States, 10016
        • New York University Medical Center
      • New York, New York, United States, 10032
        • Children's Hospital New York-Presbyterian
    • North Carolina
      • Charlotte, North Carolina, United States, 28203
        • Levine Children's Hospital
    • Ohio
      • Columbus, Ohio, United States, 43205
        • Nationwide Children's Hospital
    • Utah
      • Salt Lake City, Utah, United States, 84113
        • Primary Children's Hospital
    • Washington
      • Seattle, Washington, United States, 98105
        • Seattle Children's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 21 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria

The eligibility criteria listed below are interpreted literally and cannot be waived.

  1. Age Patients must be < 21 years of age when originally diagnosed with ALL. Patient must be > 1 year of age at study entry.
  2. Diagnosis Patients must have relapsed or refractory ALL with a M3 marrow (marrow blasts >25%). Patients with CNS I, II or III or testicular disease are eligible.
  3. Performance Level Karnofsky > 50% for patients > 10 years of age and Lansky > 50% for patients < 10 years of age.

  4. Prior Therapy Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

    1. Prior anthracycline exposure: Patients must have less than 400mg/m2 lifetime exposure of anthracycline chemotherapy.
    2. Stem Cell Transplant (SCT): Patients are eligible after allogeneic stem cell transplant as long as patients are not actively being treated for graft-versus-host-disease (GvHD).
    3. Patients should not have received previous therapy using bortezomib (Velcdade® or PS-341).
    4. During the phase I portion of the trial, there is no limit on the number of prior treatment regimens. Patients with persistent disease after an induction attempt are eligible.

    5. During the phase II portion of the trial, patients must have had two or more prior therapeutic attempts defined as:

      • Persistent initial disease after two induction attempts, or
      • Relapse after one-reinduction attempt (2nd relapse), or
      • Persistent disease after first relapse and initial re-induction attempt

      (Patients in first relapse are not eligible for the phase II portion of the study)

    6. During the phase II portion of the trial, patients must have no more than 3 prior therapeutic attempts and it must be at least 3 months since the last treatment with a "VPLD" induction/re-induction regimen.

  5. Reproductive Function

    1. Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.
    2. Female patients with infants must agree not to breastfeed their infants while on this study.
    3. Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study.

Exclusion Criteria

  1. Drug Allergies

    Patients will be excluded if they have allergies to the following:

    • Asparaginase products
    • Boron
    • Mannitol
  2. Renal Function Patients will be excluded if their serum creatinine is > 2 x the upper limit of normal for age at the institution's laboratory.

  3. Liver/Pancreatic Function

    1. Direct bilirubin > 1.5x the institutional ULN for age. A total bilirubin result that is less than 1.5 times the institutional ULN for age may be used for eligibility if a direct bilirubin result is not available.
    2. SGPT (ALT) > 4 x institutional ULN
    3. Grade 3 or greater pancreatitis as defined by the CTCAE v3.0
    4. History of any L-asparaginase induced pancreatitis
    5. Amylase or Lipase > 2 x institutional ULN
  4. Cardiac Function Patients will be excluded if their shortening fraction by echocardiogram is less than 30%.
  5. Patients with Down Syndrome are excluded.

  6. Infection

    • Patients will be excluded if they have an active uncontrolled infection.
    • Patients will be excluded if they have had a positive culture within 2 weeks of study entry.
  7. Patients with grade 2 or greater motor or sensory neuropathy per CTC 3.0 criteria.
  8. Patients planning on receiving other investigational agents while on this study. (An investigational agent is defined as any drug not currently approved for use in humans.)
  9. Patients planning on receiving other anti-cancer therapies while on this study. Hydroxyurea for cyto-reduction is allowed prior to the start of therapy.
  10. Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
  11. Patients who have started protocol therapy prior to enrollment. Patient may still enroll if IT therapy was given within 72 hours of study enrollment as part of the diagnostic lumbar procedure.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Ph 1 Dose Escalation
Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. 3+3 escalation design.
Drug: Bortezomib
Intravenous on days 1, 4, 8 and 11. Dose assigned at study entry.
Other Names:
  • Velcade
Drug: Dexamethasone
10 mg/m2/day divided BID, oral administration for 14 days.
Other Names:
  • Decadron
Drug: PEG-asparaginase
2500 IU/m2/day, intramuscular injection on Days 2, 8, 15 and 22
Other Names:
  • Oncaspar
Drug: Doxorubicin
60 mg/m2/day IV over 15 minutes on Day 1
Other Names:
  • Adriamycin
  • Rubex
Drug: Cytarabine

Given intrathecally on Day 1 of course 1 at the dose defined by age below.

  • 30 mg for patients age 1-1.99
  • 50 mg for patients age 2-2.99
  • 70 mg for patients >3 years of age
Other Names:
  • Ara-C
  • Arabinosylcytosine
  • Cytosar-U
Drug: Methotrexate

Given intrathecally to all patients who are CNS 1 at study entry on Day 15 at the dose defined by age below.

  • 8 mg for patients age 1-1.99
  • 10 mg for patients age 2-2.99
  • 12 mg for patients 3-8.99 years of age
  • 15 mg for patients >9 years of age
Other Names:
  • Amethopterin
  • Rheumatrex
  • Trexall
  • Otrexup
  • Rasuvo
Drug: Vincristine
1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22.
Other Names:
  • Oncovin
  • Leurocristine
Drug: Triple IT Therapy

Triple IT therapy will be given intrathecally on Day 8, 15, and 22 for patients who are CNS 2 and CNS 3 at study entry. Regimen/dosing as follows:

Methotrexate-

  • <2 years: 8 mg
  • 2 - <3 y: 10 mg
  • 3 - <9 y: 12 mg
  • >=9 y: 15 mg

Cytarabine:

  • <2 years: 16 mg
  • 2 - <3 y: 20 mg
  • 3 - <9 y: 24 mg
  • >=9 y: 30 mg

Hydrocortisone:

  • <2 years: 8 mg
  • 2 - <3 y: 10 mg
  • 3 - <9 y: 12 mg
  • >=9 y: 15 mg
Experimental: Ph 2 Efficacy and Safety
Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. Patients receive bortezomib at maximum tolerated dose (as established in the Phase 1 portion of the study) and are assessed for response and toxicity.
Drug: Bortezomib
Intravenous on days 1, 4, 8 and 11. Dose assigned at study entry.
Other Names:
  • Velcade
Drug: Dexamethasone
10 mg/m2/day divided BID, oral administration for 14 days.
Other Names:
  • Decadron
Drug: PEG-asparaginase
2500 IU/m2/day, intramuscular injection on Days 2, 8, 15 and 22
Other Names:
  • Oncaspar
Drug: Doxorubicin
60 mg/m2/day IV over 15 minutes on Day 1
Other Names:
  • Adriamycin
  • Rubex
Drug: Cytarabine

Given intrathecally on Day 1 of course 1 at the dose defined by age below.

  • 30 mg for patients age 1-1.99
  • 50 mg for patients age 2-2.99
  • 70 mg for patients >3 years of age
Other Names:
  • Ara-C
  • Arabinosylcytosine
  • Cytosar-U
Drug: Methotrexate

Given intrathecally to all patients who are CNS 1 at study entry on Day 15 at the dose defined by age below.

  • 8 mg for patients age 1-1.99
  • 10 mg for patients age 2-2.99
  • 12 mg for patients 3-8.99 years of age
  • 15 mg for patients >9 years of age
Other Names:
  • Amethopterin
  • Rheumatrex
  • Trexall
  • Otrexup
  • Rasuvo
Drug: Vincristine
1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22.
Other Names:
  • Oncovin
  • Leurocristine
Drug: Triple IT Therapy

Triple IT therapy will be given intrathecally on Day 8, 15, and 22 for patients who are CNS 2 and CNS 3 at study entry. Regimen/dosing as follows:

Methotrexate-

  • <2 years: 8 mg
  • 2 - <3 y: 10 mg
  • 3 - <9 y: 12 mg
  • >=9 y: 15 mg

Cytarabine:

  • <2 years: 16 mg
  • 2 - <3 y: 20 mg
  • 3 - <9 y: 24 mg
  • >=9 y: 30 mg

Hydrocortisone:

  • <2 years: 8 mg
  • 2 - <3 y: 10 mg
  • 3 - <9 y: 12 mg
  • >=9 y: 15 mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Occurrence of a Dose-Limiting Toxicity (Phase 1)
Time Frame: Beginning with the first dose of investigational product until 30 days following the last dose of bortezomib
Toxicity will be graded using the CTCAE criteria, version 3.0. Dose-limiting toxicity will be defined as any of the following events that are deemed by the investigator as possibly, probably or definitely attributable to bortezomib: Grade 3 or 4 Sensory Neuropathy; Grade 3 or 4 Neuropathic pain (Neuralgia or peripheral nerve) lasting longer than 24 hours despite medical intervention; Marrow hypoplasia, which continues 6 weeks from the start of each course (less than 10% cellularity); and Grade 4 Non-Hematologic Toxicity excluding the following: Infection (septic shock, typhlitis), Fever/Neutropenia, Fatigue, Electrolyte abnormalities, Hyper/Hypoglycemia, Nausea or Vomiting, AST/ALT/Bilirubin elevations that return to grade 1 by the time of the next course.
Beginning with the first dose of investigational product until 30 days following the last dose of bortezomib
Achievement of Complete Remission (CR)
Time Frame: Day 29 of Course 1
  • Complete Remission (CR): M1 (< 5% blasts) BM with no evidence of circulating blasts or extramedullary disease and with recovery of peripheral counts (ANC>750/uL and platelet count >75 000/uL);
  • Complete Remission without Platelet Recovery (CRp): M1 BM with no circulating blasts or extramedullary disease and recovery of ANC (>750/uL) but insufficient recovery of platelets (<75 000/uL).
  • Partial Remission (PR): the disappearance of circulating blasts and achievement of M2 (5%-25% blasts) marrow status, without new sites of extramedullary disease, and with recovery of ANC (>750/uL).
  • Stable disease (SD): not satisfying the criterion for progressive disease (PD), or a recovery of ANC (>750/uL) but fails to qualify for CR, CRp, or PR.
  • Progressive Disease (PD): increase of at least 25% in the absolute number of circulating leukemia cells, development of new sites of extramedullary disease, or other lab or clinical evidence of PD, with or without recovery of ANC or platelets.
Day 29 of Course 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Therapeutic Advances in Childhood Leukemia Consortium

Investigators

  • Study Chair: Yoav Messinger, MD, Children's Hospital and Clinics of Minnesota

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 4, 2006

Primary Completion (Actual)

February 26, 2011

Study Completion (Actual)

February 26, 2011

Study Registration Dates

First Submitted

February 23, 2007

First Submitted That Met QC Criteria

February 26, 2007

First Posted (Estimate)

February 27, 2007

Study Record Updates

Last Update Posted (Actual)

February 19, 2020

Last Update Submitted That Met QC Criteria

February 7, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • T2005-003

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Lymphoblastic Leukemia

Clinical Trials on Bortezomib

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe